Hugel, Inc. (KOSDAQ:145020)
South Korea · Delayed Price · Currency is KRW | Market Cap | 2.63T -8.1% |
| Revenue (ttm) | 404.19B +11.1% |
| Net Income | 142.27B +27.0% |
| EPS | 12,727.07 +29.4% |
| Shares Out | 10.80M |
| PE Ratio | 19.13 |
| Forward PE | 19.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 57,091 |
| Average Volume | 129,468 |
| Open | 242,500 |
| Previous Close | 250,000 |
| Day's Range | 236,500 - 245,000 |
| 52-Week Range | 208,500 - 392,000 |
| Beta | 0.56 |
| RSI | 46.24 |
| Earnings Date | Feb 11, 2026 |
About Hugel
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years o... [Read more]
Financial Performance
In 2024, Hugel's revenue was 373.05 billion, an increase of 16.69% compared to the previous year's 319.70 billion. Earnings were 135.81 billion, an increase of 45.92%.
Financial StatementsNews
Hugel hits record net sales, operating profit in Q3
- Net sales registered KRW105.1 billion and operating profit achieved KRW53.4 billion , up 23.9% and 54.5% on-year, respectively - Net sales of toxin rose 41% on-year, thanks to initial shipment to th...